Please use this identifier to cite or link to this item:
Title: Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
Authors: Haddad, Albert
Jabbour, Michel
Bulbul, Muhammad
Keywords: 5ARI, 5α-reductase inhibitor
AE, adverse event
Benign prostatic hyperplasia
ED, erectile dysfunction
EF, erectile function (domain)
Erectile dysfunction
IIEF, International Index of Erectile Function
NO, nitric oxide
PDE5 inhibitor
PDE5, phosphodiesterase type 5
QoL, quality of life
ROCK, Rho-associated protein kinase
RhoA, Ras homologue gene family member A
cGMP, cyclic guanosine monophosphate
Issue Date: 2015
Part of: Arab Journal of Urology
Volume: 13
Issue: 3
Start page: 155
End page: 161
Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor.
ISSN: 2090-598X
DOI: 10.1016/j.aju.2015.06.004
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Nov 25, 2023

Record view(s)

checked on Nov 29, 2023

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.